Visual Universitätsmedizin Mainz

PD Dr. med. Marcus-Alexander Wörns

Priv.-Doz. Dr. med. Wörns
Funktionen: Leitender Oberarzt, Personaloberarzt, Leiter der Leber-, HCC- und Onkologischen Ambulanz
Qualifikationen: Facharzt für Innere Medizin, Gastroenterologe
marcus-alexander.woerns@unimedizin-mainz.de

Sekretariat

Boettel
Jana Boettel

06131 17-7104
06131 17-2728
jana.boettel@unimedizin-mainz.de

Geb. 601, 1. Etage, Zimmer 107

I. Medizinische Klinik und Poliklinik

Universitätsmedizin Mainz

Langenbeckstrasse 1

55131 Mainz

Tel. 06131 17-7104

Fax 06131 17-2728

 

Klinische Schwerpunkte

  • Hepatologie
  • Hepatozelluläres Karzinom
  • Gastrointestinale Onkologie

Wissenschaftliche Schwerpunkte

  • Targeted Therapy beim Hepatozellulären Karzinom (HCC)
  • Bedeutung des NF-kappaB Signalweges für die hepatische und intestinale Inflammation und Karzinogenese

Kooperationen

  • Dr. Arndt Weinmann, I. Medizinische Klinik
  • PD Dr. Jörn Schattenberg, I. Medizinische Klinik
  • Prof. Dr. rer. nat. Ari Waisman, Institut für Molekulare Medizin, Mainz
  • Prof Dr. Henning Schulze-Bergkamen, Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg

Mitgliedschaften

  • Deutsche Gesellschaft für Verdauungs- und Stoffwechselerkrankungen (DGVS)
  • German Association for the Study of the Liver (GASL)
  • European Association for the Study of the Liver (EASL)
  • Deutsche Gesellschaft für Innere Medizin (DGIM)
  • Deutsche Gesellschaft für Immunologie (DGfI)
  • Arbeitsgemeinschaft Internistische Onkologie (AIO)
  • Gastroenterologische Arbeitsgemeinschaft Rheinland-Pfalz/Saarland (GARPS)

Reviewer für wissenschaftliche Zeitschriften

  • American Journal of Gastroenterology
  • Journal of Hepatology
  • Journal of Translational Medicine
  • Zeitschrift für Gastroenterologie
  • Digestive and Liver Disease
  • Liver International, Onkologie

Publikationen (Auswahl)

  1. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. Wörns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstätter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A. Dig Liver Dis. 2013 May;45(5):408-13. Epub 2012 Nov 21.
  2. Midterm follow-up after DC-BEAD™-TACE of hepatocellular carcinoma (HCC). Skowasch M, Schneider J, Otto G, Weinmann A, Wörns MA, Dueber C, Pitton MB. Eur J Radiol. 2012 Dec;81(12):3857-61. Epub 2012 Jul 25. PMID: 22840383 [PubMed - in process]
  3. IgG4-related sclerosing cholangitis mimicking cholangiocarcinoma. Nguyen-Tat M, Gamstätter T, Marquardt JU, Geißinger E, Schadmand-Fischer S, Lang H, Siegel E, Schuchmann M, Galle PR, Wörns MA. Z Gastroenterol. 2012 Sep;50(9):1008-12. Epub 2012 Sep 10. PMID: 22965631 [PubMed - indexed for MEDLINE]
  4. Clinicopathologic features and prognosis of young patients with hepatocellular carcinoma in a large German cohort. Niederle IM, Wörns MA, Koch S, Nguyen-Tat M, Düber C, Otto G, Schuchmann M, Galle PR, Weinmann A. J Clin Gastroenterol. 2012 Oct;46(9):775-8. PMID: 22914348 [PubMed - indexed for MEDLINE]
  5. Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice. Urbanik T, Boger RJ, Longerich T, Becker K, Ehrenberg KR, Hövelmeyer N, Hahn M, Schuchmann M, Jäger D, Waisman A, Wörns MA, Schulze-Bergkamen H. J Hepatol. 2012 Nov;57(5):995-1003. Epub 2012 Jun 21. PMID: 22728872 [PubMed - in process]
  6. Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver. Wörns MA, Bosslet T, Victor A, Koch S, Hoppe-Lotichius M, Heise M, Hansen T, Pitton MB, Niederle IM, Schuchmann M, Weinmann A, Düber C, Galle PR, Otto G. Scand J Gastroenterol. 2012 Jun;47(6):718-28. Epub 2012 Apr 4. PMID: 22472070 [PubMed - indexed for MEDLINE]
  7. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Weinmann A, Niederle IM, Koch S, Hoppe-Lotichius M, Heise M, Düber C, Schuchmann M, Otto G, Galle PR, Wörns MA. Dig Liver Dis. 2012 May;44(5):432-7. Epub 2012 Jan 20. PMID: 22265328 [PubMed - indexed for MEDLINE]
  8. [Hepatocellular carcinoma: what's new?]. Teufel A, Marquardt JU, Galle PR, Wörns MA. Dtsch Med Wochenschr. 2012 Feb;137(5):210-3. doi: 10.1055/s-0031-1292890. Epub 2012 Jan 16. Review. German. PMID: 22250042 [PubMed - indexed for MEDLINE]
  9. AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature. Gamstätter T, Weinmann A, Schadmand-Fischer S, Spies PR, Niederle IM, Schuchmann M, Galle PR, Wörns MA. Onkologie. 2011;34(10):538-42. Epub 2011 Sep 16.
  10. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. Urbanik T, Köhler BC, Boger RJ, Wörns MA, Heeger S, Otto G, Hövelmeyer N, Galle PR, Schuchmann M, Waisman A, Schulze-Bergkamen H. Int J Oncol. 2011 Jan;38(1):121-31. PMID: 21109933 [PubMed - indexed for MEDLINE]
  11. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Wörns MA, Schuchmann M, Düber C, Otto G, Galle PR, Weinmann A. Oncology. 2010;79(1-2):85-92. Epub 2010 Nov 12. PMID: 21071995 [PubMed - indexed for MEDLINE]
  12. Future perspectives in hepatocellular carcinoma. Wörns MA, Galle PR. Dig Liver Dis. 2010 Jul;42 Suppl 3:S302-9. Review. PMID: 20547319 [PubMed - indexed for MEDLINE]
  13. Novel inhibitors in development for hepatocellular carcinoma. Wörns MA, Galle PR. Expert Opin Investig Drugs. 2010 May;19(5):615-29. PMID: 20374038 [PubMed - indexed for MEDLINE]
  14. Systemic therapies in hepatocellular carcinoma. Wörns MA, Weinmann A, Schuchmann M, Galle PR. Dig Dis. 2009;27(2):175-88. Epub 2009 Jun 22. Review. PMID: 19546557 [PubMed - indexed for MEDLINE]
  15. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR. J Clin Gastroenterol. 2009 May-Jun;43(5):489-95. PMID: 19247201 [PubMed - indexed for MEDLINE]
  16. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Wörns MA, Teufel A, Kanzler S, Shrestha A, Victor A, Otto G, Lohse AW, Galle PR, Höhler T. Am J Gastroenterol. 2008 Jan;103(1):138-46. Epub 2007 Oct 26. PMID: 17970833 [PubMed - indexed for MEDLINE]
  17. Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD. Hövelmeyer N, Wunderlich FT, Massoumi R, Jakobsen CG, Song J, Wörns MA, Merkwirth C, Kovalenko A, Aumailley M, Strand D, Brüning JC, Galle PR, Wallach D, Fässler R, Waisman A. J Exp Med. 2007 Oct 29;204(11):2615-27. Epub 2007 Oct 8. PMID: 17923499 [PubMed - indexed for MEDLINE]
  18. Single center experience over a 5-year period with sequential transarterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC) Herber SC, Otto G, Wörns MA, Moench C, Kanzler S, Junginger T, Schneider J, Schuchmann M, Kummer I, Manzl N, Düber C, Pitton MB. Rofo. 2007 Mar;179(3):289-99. German. PMID: 17325996 [PubMed - indexed for MEDLINE]
  19. Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels-a study in twins. Wörns MA, Victor A, Galle PR, Höhler T. Genes Immun. 2006 Oct;7(7):600-5. Epub 2006 Aug 10. PMID: 16900203 [PubMed - indexed for MEDLINE]
  20. Five cases of de novo inflammatory bowel disease after orthotopic liver transplantation. Wörns MA, Lohse AW, Neurath MF, Croxford A, Otto G, Kreft A, Galle PR, Kanzler S. Am J Gastroenterol. 2006 Aug;101(8):1931-7. Epub 2006 Jun 22. PMID: 16790037 [PubMed - indexed for MEDLINE]